← Back to Search

MPO Inhibitor

Mitiperstat for COPD (CRESCENDO Trial)

Verified Trial
Phase 2
Recruiting
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be deemed as high risk of exacerbations as defined by: >= 1 moderate or severe exacerbation in the previous 24 months; or frequent productive cough; or post-bronchodilator (BD) forced expiratory volume in the first second (FEV1) < 50% predicted
Participants must be 40-80 years of age inclusive, at the time of signing informed consent form (ICF)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to week 12 and week 24
Awards & highlights

CRESCENDO Trial Summary

This trial will test a drug to see if it can help adults with COPD feel better and be safe.

Who is the study for?
Adults aged 40-80 with moderate to severe COPD, who are current or ex-smokers with a significant smoking history. They must have had at least one exacerbation in the past two years or show other signs of high risk for exacerbations and be on a stable regimen of COPD therapy.Check my eligibility
What is being tested?
The trial is testing Mitiperstat (AZD4831), an experimental drug, against a placebo to see if it's effective and safe for treating chronic obstructive pulmonary disease (COPD) in adults.See study design
What are the potential side effects?
While specific side effects of Mitiperstat are not listed, common risks may include reactions at the site of administration, potential respiratory issues due to underlying COPD conditions, and general medication-related side effects like nausea or headaches.

CRESCENDO Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am at high risk of lung issues due to frequent coughs or severe breathing test results.
Select...
I am between 40 and 80 years old.
Select...
I have been diagnosed with moderate to severe COPD.
Select...
I have smoked at least 10 packs of cigarettes a year.
Select...
I have been on a stable medication regimen for my condition for at least 3 months.

CRESCENDO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to week 12 and week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to week 12 and week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the effect of mitiperstat (AZD4831) as compared to placebo on the time to first COPD Composite Exacerbation (CompEx) event in patients with moderate to severe COPD.
Secondary outcome measures
To assess the PK of mitiperstat (AZD4831) in patients with moderate to severe COPD
To assess the effect of mitiperstat (AZD4831) compared to placebo in disease impact in patients with moderate to severe COPD.
To assess the effect of mitiperstat (AZD4831) compared to placebo on respiratory symptoms in patients with moderate to severe COPD.
+3 more

CRESCENDO Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Mitiperstat (AZD4831)Experimental Treatment1 Intervention
Approximately 144 participants will be randomised to receive mitiperstat (AZD4831).
Group II: PlaceboPlacebo Group1 Intervention
Approximately 144 participants will be randomised to receive placebo.

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,243 Previous Clinical Trials
288,527,919 Total Patients Enrolled

Media Library

AZD4831 (MPO Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05492877 — Phase 2
Chronic Obstructive Pulmonary Disease Research Study Groups: Mitiperstat (AZD4831), Placebo
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: AZD4831 Highlights & Side Effects. Trial Name: NCT05492877 — Phase 2
AZD4831 (MPO Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05492877 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are my qualifications suitable for enrollment in this research project?

"To take part in this clinical trial, participants must have a diagnosis of chronic obstructive airway disease and be between 40-80 years old. 288 individuals are needed for the completion of this study."

Answered by AI

How many treatment centers in the United States are conducting this clinical trial?

"Currently, 15 clinical trial sites are recruiting participants. Said locations encompass Newport Beach, Clearwater and Lake Wales amongst other cities. Thus it is beneficial to pick the closest clinic if you decide to partake in this study so that travel is kept at a minimum."

Answered by AI

Could you provide insight into the risks associated with AZD4831?

"Our experts at Power have given AZD4831 a score of 2 on their safety scale, as this is only in Phase 2 trials and there has been no evidence yet that it is effective."

Answered by AI

Are elderly individuals being accepted into this experiment?

"This medical study has a limited age range of 40 to 80 years old. There are 35 trials for younger individuals and 467 studies available to those over 65."

Answered by AI

Are there any participation slots open for this trial?

"Per the details on clinicaltrials.gov, this medical trial is still seeking participants. Initially posted in November of 2022, it was most recently updated in December of that same year."

Answered by AI

How many individuals are allowed to register for the experiment?

"Affirmative. Per the details listed on clinicaltrials.gov, this research is actively enrolling participants with an original posting date of November 14th 2022 and a most recent update on December 12th 2022. The study requires 288 individuals across 15 different sites to volunteer for it."

Answered by AI

Who else is applying?

What site did they apply to?
Clinical Research of West Florida
Research Site
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

I've tried many inhaled medications, and it's getting worse, and most of the medications work for a time of a yr or less then no longer help. Symptoms more severe in winter months.
PatientReceived 1 prior treatment
~16 spots leftby May 2024